NEW
YORK, Jan. 4, 2023 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery platforms, today announced that the United
States Patent and Trademark Office has granted the Company a patent
titled "Methods and Compositions for Treating Diabetes." The
patent serves as an extension to a patent previously granted in
May 2022 and addresses methods and
compositions for treating diabetes mellitus through oral
pharmaceutical compositions comprising insulin in combination with
Glucagon-like Peptide 1 (GLP-1).
"With the topline data for our first Phase 3 oral insulin trial
expected soon, we continue to further fortify Oramed's leading
position with respect to intellectual property assets addressing
the oral delivery of therapeutic proteins currently only available
via injection," stated Oramed CEO Nadav
Kidron.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq: ORMP) (TASE: ORMP) is a platform
technology pioneer in the field of oral delivery solutions for
drugs currently delivered via injection. The Company's novel
Protein Oral Delivery (POD™) technology is designed to protect drug
integrity and increase absorption. Oramed is seeking to transform
the treatment of diabetes through its proprietary lead candidate,
ORMD-0801, which is being evaluated in two pivotal Phase 3 trials
and has the potential to be the first commercial oral insulin
capsule for the treatment of diabetes. In addition, Oramed is
developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule
(ORMD-0901). Oramed has offices in the United States and Israel. For more information, please visit
www.oramed.com
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential of
ORMD-0801 to be the first commercial oral insulin capsule for the
treatment of diabetes. In addition, historic results of scientific
research and clinical trials do not guarantee that the conclusions
of future research or trials will suggest identical or even similar
conclusions. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed' s
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact:
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com
Logo -
https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/oramed-granted-us-combination-therapy-patent-for-oral-glp-1--insulin-for-the-treatment-of-diabetes-301713190.html
SOURCE Oramed Pharmaceuticals Inc.